This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoggard, P. G.
Right arrow Articles by Back, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoggard, P. G.
Right arrow Articles by Back, D. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Jun 1997, 1231-1236, Vol 41, No. 6
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro

PG Hoggard, S Kewn, MG Barry, SH Khoo and DJ Back
Department of Pharmacology & Therapeutics, University of Liverpool, United Kingdom.

Drugs commonly administered to patients infected with the human immunodeficiency virus (HIV) have been studied for their propensity to alter the intracellular phosphorylation of the anti-HIV nucleoside analog stavudine (2',3'-dideoxy-2',3'-didehydrothymidine; d4T) in peripheral blood mononuclear cells (PBMCs) and U937 cells in vitro. PBMCs isolated from the blood of healthy volunteers were stimulated by the mitogen phytohemagglutinin (10 microg/ml) for 72 h. Stimulated PBMCs (3 x 10(6) cells/plate) were then incubated with [3H]d4T (0.65 microCi; 3 microM) and either acyclovir, dapsone, ddC, ddI, fluconazole, foscarnet, ganciclovir, itraconazole, lobucavir, ranitidine, ribavirin, rifampin, sorivudine, sulfamethoxazole, trimethoprim, lamivudine (3TC), zidovudine, or thymidine (30 and 300 microM) for 24 h. Doxorubicin and drugs showing some evidence of inhibition were also studied at 0.3 and 3 microM. Cells were extracted overnight with 60% methanol prior to analysis by radiometric high- performance liquid chromatography. Additional data for nine of the drugs were obtained by incubation with [3H]d4T in U937 cells for 24 h. The effect of d4T (0.2 to 20 microM) on zidovudine (0.65 microCi; 0.018 microCi) phosphorylation was also studied. Zidovudine significantly reduced d4T total phosphates in PBMCs and U937 cells (in PBMCs to 33% [P < 0.001] and 17% [P < 0.001] of that in control cells at 3 and 30 microM, respectively). A small reduction in zidovudine phosphorylation was seen with d4T but only at d4T:zidovudine ratios of 100 and 1,000. Of the other compounds screened, only thymidine, ribavirin, and doxorubicin produced inhibition of d4T phosphorylation in both PBMCs and U937 cells. However, doxorubicin was cytotoxic at 3 microM. The decrease in d4T phosphorylation in the presence of ribavirin is consistent with previous findings with zidovudine. Although ddC significantly inhibited the phosphorylation of d4T in PBMCs, this was not seen in U937 cells, and it is probable that the findings in PBMCs are related to mitochondrial toxicity [based on 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyl tetrazolium bromide cytotoxicity assay]. The only drugs screened which may interfere with d4T phosphorylation at clinically relevant concentrations were zidovudine, ribavirin, and doxorubicin.


This article has been cited by other articles:

  • Pruvost, A., Negredo, E., Theodoro, F., Puig, J., Levi, M., Ayen, R., Grassi, J., Clotet, B. (2009). Pilot Pharmacokinetic Study of Human Immunodeficiency Virus-Infected Patients Receiving Tenofovir Disoproxil Fumarate (TDF): Investigation of Systemic and Intracellular Interactions between TDF and Abacavir, Lamivudine, or Lopinavir-Ritonavir. Antimicrob. Agents Chemother. 53: 1937-1943 [Abstract] [Full Text]  
  • Garvey, E. P., Johns, B. A., Gartland, M. J., Foster, S. A., Miller, W. H., Ferris, R. G., Hazen, R. J., Underwood, M. R., Boros, E. E., Thompson, J. B., Weatherhead, J. G., Koble, C. S., Allen, S. H., Schaller, L. T., Sherrill, R. G., Yoshinaga, T., Kobayashi, M., Wakasa-Morimoto, C., Miki, S., Nakahara, K., Noshi, T., Sato, A., Fujiwara, T. (2008). The Naphthyridinone GSK364735 Is a Novel, Potent Human Immunodeficiency Virus Type 1 Integrase Inhibitor and Antiretroviral. Antimicrob. Agents Chemother. 52: 901-908 [Abstract] [Full Text]  
  • Holdich, T., Shiveley, L. A., Sawyer, J. (2007). Effect of Lamivudine on the Plasma and Intracellular Pharmacokinetics of Apricitabine, a Novel Nucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers. Antimicrob. Agents Chemother. 51: 2943-2947 [Abstract] [Full Text]  
  • Ramanathan, S., Cheng, A., Mittan, A., Ebrahimi, R., Kearney, B. P. (2006). Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects.. J Clin Pharmacol 46: 559-566 [Abstract] [Full Text]  
  • Melendez, M., Blanco, R., Delgado, W., Garcia, R., Santana, J., Garcia, H., Rosario, O., Rodriguez, J. F. (2006). Lack of Evidence for In Vivo Transformation of Zidovudine Triphosphate to Stavudine Triphosphate in Human Immunodeficiency Virus-Infected Patients. Antimicrob. Agents Chemother. 50: 835-840 [Abstract] [Full Text]  
  • Rodriguez-Torres, M., Torriani, F. J., Soriano, V., Borucki, M. J., Lissen, E., Sulkowski, M., Dieterich, D., Wang, K., Gries, J.-M., Hoggard, P. G., Back, D., for the APRICOT Study Group, (2005). Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study. Antimicrob. Agents Chemother. 49: 3997-4008 [Abstract] [Full Text]  
  • Mauss, S., Rockstroh, J. K. (2005). HCV/HIV-coinfection--is there a state of the art after APRICOT and RIBAVIC?. J Antimicrob Chemother 56: 615-618 [Abstract] [Full Text]  
  • Pruvost, A., Negredo, E., Benech, H., Theodoro, F., Puig, J., Grau, E., Garcia, E., Molto, J., Grassi, J., Clotet, B. (2005). Measurement of Intracellular Didanosine and Tenofovir Phosphorylated Metabolites and Possible Interaction of the Two Drugs in Human Immunodeficiency Virus-Infected Patients. Antimicrob. Agents Chemother. 49: 1907-1914 [Abstract] [Full Text]  
  • Winnock, M., Salmon-Ceron, D., Dabis, F., Chene, G. (2004). Interaction between HIV-1 and HCV infections: towards a new entity?. J Antimicrob Chemother 53: 936-946 [Abstract] [Full Text]  
  • Zhang, H., Zhou, Y., Alcock, C., Kiefer, T., Monie, D., Siliciano, J., Li, Q., Pham, P., Cofrancesco, J., Persaud, D., Siliciano, R. F. (2004). Novel Single-Cell-Level Phenotypic Assay for Residual Drug Susceptibility and Reduced Replication Capacity of Drug-Resistant Human Immunodeficiency Virus Type 1. J. Virol. 78: 1718-1729 [Abstract] [Full Text]  
  • Sulkowski, M. S., Thomas, D. L. (2003). Hepatitis C in the HIV-Infected Person. ANN INTERN MED 138: 197-207 [Abstract] [Full Text]  
  • Mohsen, A H, Easterbrook, P, Taylor, C B, Norris, S (2002). Hepatitis C and HIV-1 coinfection. Gut 51: 601-608 [Abstract] [Full Text]  
  • King, R. W., Klabe, R. M., Reid, C. D., Erickson-Viitanen, S. K. (2002). Potency of Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) Used in Combination with Other Human Immunodeficiency Virus NNRTIs, NRTIs, or Protease Inhibitors. Antimicrob. Agents Chemother. 46: 1640-1646 [Abstract] [Full Text]  
  • Bruno, R., Sacchi, P., Filice, G., Yokozaki, S., Takamatsu, J., Nakano, I., Katano, Y., Toyoda, H., Hayashi, K., Hayakawa, T., Fukuda, Y. (2001). Hepatitis C virus RNA dynamics during antiretroviral therapy. Blood 97: 3318-3319 [Full Text]  
  • Piscitelli, S. C., Gallicano, K. D. (2001). Interactions among Drugs for HIV and Opportunistic Infections. NEJM 344: 984-996 [Full Text]  
  • Conry, J. M. (2000). Significant Drug Interactions in the HIV Patient. Journal of Pharmacy Practice 13: 499-514 [Abstract]  
  • Zylberberg, H, Benhamou, Y, Lagneaux, J L, Landau, A, Chaix, M-L, Fontaine, H, Bochet, M, Poynard, T, Katlama, C, Pialoux, G, Brechot, C, Pol, S (2000). Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 47: 694-697 [Abstract] [Full Text]  
  • de Muys, J.-M., Gourdeau, H., Nguyen-Ba, N., Taylor, D. L., Ahmed, P. S., Mansour, T., Locas, C., Richard, N., Wainberg, M. A., Rando, R. F. (1999). Anti-Human Immunodeficiency Virus Type 1 Activity, Intracellular Metabolism, and Pharmacokinetic Evaluation of 2'-Deoxy-3'-Oxa-4'-Thiocytidine. Antimicrob. Agents Chemother. 43: 1835-1844 [Abstract] [Full Text]  
  • Piscitelli, S. C., Kelly, G., Walker, R. E., Kovacs, J., Falloon, J., Davey, R. T. Jr., Raje, S., Masur, H., Polis, M. A. (1999). A Multiple Drug Interaction Study of Stavudine with Agents for Opportunistic Infections in Human Immunodeficiency Virus-Infected Patients. Antimicrob. Agents Chemother. 43: 647-650 [Abstract] [Full Text]  
  • (1998). Antiretroviral Therapy and Medical Management of Pediatric HIV Infection. Pediatrics 102: 1005-1062 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»